Skip to main content Skip to main navigation menu Skip to site footer

Melanoma maligna orbita: sebuah laporan kasus

  • Ni Luh Putu Nurindah Sukmawati ,
  • Putu Yuliawati ,
  • Ni Made Laksmi Utari ,

Abstract

Introduction: Orbital melanoma (OM) is the most common type of primary intraocular neoplasm in adults. Although the incidence of OM is only 5% of melanoma tumors, OM causes death in 13% of melanoma tumors. The management of orbital melanoma originating from the uveal tissue is still controversial between surgical and nonsurgical therapy.

Case Report: A male patient, 63 years old, complained that the patient's right eye was said to have appeared a lump since five months ago with a size of 6 x 6 x 7 cm, blackish red in color with clinical signs of malignancy. The patient underwent orbital exenteration and the patient's condition had no recurrence or other complaints until four months after the procedure.

Conclusion: Orbital melanoma of uveal origin is a complex malignancy that requires a multidisciplinary approach to therapy and management. Early detection and adequate therapy are very important in increasing survival rates.

 

Pendahuluan: Melanoma orbita (MO) merupakan tipe yang paling sering dari neoplasma primer intraokular pada dewasa. Meskipun insiden MO hanya 5% dari tumor melanoma, namun MO menimbulkan kematian pada 13% akibat tumor melanoma. Tatalaksana melanoma orbita yang berasal dari jaringan uvea sampai saat ini masih kontroversial antara terapi bedah dan nonbedah. Laporan Kasus: Seorang pasien laki-laki, 63 tahun, mengeluh mata kanan pasien dikatakan muncul benjolan sejak lima bulan yang lalu dengan ukuran 6 x 6 x 7 cm, berwarna merah kehitaman dengan klinis mengarah keganasan. Pasien dilakukan eksenterasi orbita dan kondisi pasien tidak terdapat kekambuhan ataupun keluhan lain hingga empat bulan setelah tindakan.

Simpulan: Melanoma orbita yang berasal dari uvea merupakan keganasan yang kompleks yang membutuhkan pendekatan multidisiplin dalam terapi dan tatalaksana. Deteksi dini dan terapi yang adekuat sangat penting dalam upaya meningkatkan angka ketahanan hidup.

References

  1. Shields JA, Shields CL, Brotman HK, Carvalho C, Perez N, Eagle RC
  2. Jr. Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture.
  3. Ophthalmic Plast Reconstr Surg. 2001;17:346-354.
  4. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881-1185.
  5. Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol. 2015; 99:1550-1553.
  6. Rose AM, Cowen S, Jayasena CN, Verity DH, Rose GE. Presentation, treatment, and prognosis of secondary melanoma within the orbit. Front. Oncol. 2017;7:125.
  7. Johansson CC, Mougiakakos D, Trocme E, All-Ericsson C, Economou MA, Larsson O, dkk. Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer. 2010;126:2682-2689.
  8. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44: 4651-4659.
  9. Singh P, Sen S, Banerjee M, Meel R. Choroidal melanoma masquerading as orbital cellulitis. BMJ Case Reports CP. 2018;11 (1):1-4.
  10. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639-1643.
  11. Kiratli H, Koç İ. Orbital exenteration: institutional review of evolving trends in indications and rehabilitation techniques. Orbit. 2018;37(3):179-186.
  12. Adetunji MO, McGeehan B, Lee V, Maguire MG, Briceño CA. Primary orbital melanoma: A report of a case and comprehensive review of the literature. Orbit. 2021;40(6):461-469.
  13. Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013). Ocular oncology and pathology. 2018;4(3):145-151.
  14. Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363-1372.
  15. Berus T, Halon A, Markiewicz A, Orlowska-Heitzman J, Romanowska-Dixon B, Donizy P. Clinical, histopathological and cytogenetic prognosticators in uveal melanoma–A comprehensive review. Anticancer research. 2017;37(12):6541-6549.
  16. Krantz Ba, Dave N, Komatsubara KM. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279–289.
  17. Frizziero L, Midena E, Trainiti S, Londei D, Bonaldi L, Bini S, dkk. Uveal melanoma biopsy: A review. Cancers. 2019;11(8):1075.
  18. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120(12):1665-1671.
  19. Echegaray JJ, Bechrakis NE, Singh N, Bellerive C, Singh AD. Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose. Ocular oncology and pathology. 2017;3(3):193-198.
  20. Lane A, Kim I, Gragoudas E. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmology. 2018;136(9):981.
  21. Rahman I, Cook AE, Leatherbarrow B. Orbital exenteration: A 13 year Manchester experience. Br J Ophthalmol. 2005;89(10):1335–1340.
  22. Reichstein D, Karan K. Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. Current opinion in ophthalmology. 2018;29(3):191-198.
  23. Naseripour M, Jaberi R, Sedaghat A. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy. 2016;8:66–73.
  24. Francis JH, Barker CA, Yin VT, Carvajal RD, Chapman P, Abramson DH, dkk. Chemoreduction of orbital recurrence of uveal melanoma by intra-arterial melphalan. Ocular oncology and pathology. 2019;5(3):186-189.
  25. Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117:1170–1178.
  26. Sato T, Nathan PD, Hernandez-Aya L, Sacco JJ, Orloff MM, Visich J. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100- directed TCR IMCgp100: overall survival findings. J Clin Oncol. 2018;36(15suppl):9521.
  27. Shildkrot Y, Wilson MW. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Current opinion in ophthalmology. 2009;20(6):504-510.
  28. Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, dkk. The latest on uveal melanoma research and clinical trials: updates from the cure ocular melanoma (CURE OM) Science Meeting (2019). Clinical Cancer Research. 2021;27(1):28-33.
  29. Höglund M, Gisselsson D, Hansen GB, White VA, Säll T, Mitelman F, dkk. Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gainsin melanoma karyotypic evolution. Int J Cancer. 2004;108:57-65.
  30. Schank TE. Hassel JC. Immunotherapies for the treatment of uveal Melanoma—History and future. Cancers. 2019;11(8):1048.
  31. Jain, S., and Jain, P. Rehabilitation of orbital cavity after orbital exenteration using polymethyl methacrylate orbital prosthesis. The Journal of the Indian Prosthodontic Society. 2016; 16(1): 100.

How to Cite

Sukmawati, N. L. P. N., Putu Yuliawati, & Ni Made Laksmi Utari. (2022). Melanoma maligna orbita: sebuah laporan kasus. Intisari Sains Medis, 13(1), 258–263. https://doi.org/10.15562/ism.v13i1.1269

HTML
0

Total
0

Share

Search Panel

Ni Luh Putu Nurindah Sukmawati
Google Scholar
Pubmed
ISM Journal


Putu Yuliawati
Google Scholar
Pubmed
ISM Journal


Ni Made Laksmi Utari
Google Scholar
Pubmed
ISM Journal